NCT00503490View on ClinicalTrials.gov

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Cystic Fibrosis
Interventions
DRUG

MP-376 (Levofloxacin solution for Inhalation)

40, 80, 120mg RDD

DRUG

placebo

BID

Trial Locations (14)

11040

New Hyde Park

12208

Albany

29203

Charleston

29425

Charleston

32801

Orlando

43205

Columbus

49007

Kalamazoo

68154

Omaha

73112

Oklahoma City

78212

San Antonio

84132

Salt Lake City

90033

Los Angeles

92037

La Jolla

94303

Palo Alto

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00503490 - Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis | Biotech Hunter | Biotech Hunter